Comparing the current results to its competitors, Karuna Therapeutics Inc reported Revenue decrease in the 3 quarter 2023 year on year by 0 %, despite the revenue increase by the most of its competitors of 38.77 %, recorded in the same quarter.
December 22, 2023
Bristol Myers Squibb Bolsters Neuroscience Portfolio with Karuna Therapeutics AcquisitionPrinceton, N.J. and Boston - In a strategic move to expand its neuroscience portfolio, pharmaceutical giant Bristol Myers Squibb (BMY) has announced its acquisition of Karuna Therapeutics, Inc. (KRTX), a clinical-stage biopharmaceutical company focused on developing novel treatments for neuropsychiatric disorders. The merger agreement, involving a cash deal worth $14.0 billion ($12.7 billion net of estimated cash acquired), has been unanimously approved by the boards of both companies.The acquisition comes as Bristol Myers Squibb recognizes the growing need for innovative therapies to address the unmet medical needs of p...
November 29, 2023
Karuna Therapeutics, a biopharmaceutical company dedicated to improving the lives of individuals with psychiatric and neurological disorders, has recently announced a significant development in their mission. The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for KarXT (xanomeline-trospium), a potential treatment for adults suffering from schizophrenia. This marks a crucial step towards providing an innovative therapy for those affected by this debilitating condition. Schizophrenia is a complex mental disorder that affects approximately 1% of the global population. It is characterized by a combination of symptoms, including hallucinations, delusions, disorganized thin...
November 16, 2023
Karuna Therapeutics Announces Positive Results from Phase 1b Trial of KarXT in Schizophrenia: Findings Yield Encouraging Outcomes on Ambulatory Blood Pressure Monitoring Boston-based biopharmaceutical company, Karuna Therapeutics, has revealed promising results from its Phase 1b trial evaluating the impact of KarXT (xanomeline-trospium) on 24-hour ambulatory blood pressure in adults with schizophrenia. The study, which spanned eight weeks and employed an open-label design, demonstrates that the administration of KarXT was not associated with any noteworthy increases in blood pressure. Schizophrenia, a complex and severe mental disorder, affects millions of people worldwide. Individuals living with th...
Xenon Pharmaceuticals Inc operates in the biopharmaceutical industry, with a focus on discovering and developing innovative therapeutics. Their business model centers around leveraging their proprietary discovery platform to identify and advance potential drug candidates to address unmet medical needs. Through collaborations, licensing agreements, and internal development efforts, Xenon aims to bring new treatments to patients and create value for their stakeholders.
Biomarin Pharmaceutical Inc operates as a biotechnology company, specializing in the development and commercialization of innovative therapies for rare genetic diseases. Their business model revolves around conducting extensive research and development to identify and address unmet medical needs, manufacturing and marketing their approved products, and collaborating with strategic partners to maximize the reach and impact of their therapies worldwide. By focusing on rare diseases, Biomarin leverages their expertise to provide targeted and innovative treatments, ultimately improving the lives of patients in need.
Axsome Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for central nervous system (CNS) disorders. Their business model revolves around conducting clinical trials to demonstrate the safety and efficacy of their drug candidates, obtaining regulatory approvals, and subsequently marketing and selling these therapies in the market to improve patient outcomes and generate revenue. By targeting CNS disorders, Axsome Therapeutics aims to address unmet medical needs and provide solutions for patients suffering from these conditions.
Adhera Therapeutics Inc's business model revolves around developing and commercializing innovative medication adherence solutions. They leverage technology to provide patients with tools and support systems that help them adhere to prescribed treatments. By focusing on improving medication adherence rates, Adhera Therapeutics aims to enhance patient outcomes and reduce healthcare costs for both individuals and the healthcare industry.
Amylyx Pharmaceuticals Inc's business model revolves around researching, developing, and commercializing potential therapies for neurodegenerative diseases. They aim to identify promising drug candidates, conduct preclinical and clinical trials, and ultimately gain regulatory approval to market and sell their products. By focusing on innovative treatments, Amylyx Pharmaceuticals Inc aims to address unmet medical needs in the field of neurodegenerative disorders.
Sources:
Karuna Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Karuna Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
